Bi-aryl meta-pyrimidine inhibitors of kinases

Disclosed are substituted pyrimidine compounds of formula (A) where the substituents are as disclosed in the description. Examples of compounds of formula (A) are: N-tert-Butyl-2-methyl-5- { 5-methyl-2-[ 4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino ]-pyrimidin-4-ylamino} -benzenesulfonamide; N4-(3-tert-...

Full description

Saved in:
Bibliographic Details
Main Authors HOOD, JOHN, MC PHERSON, ANDREW, PATHAK, VED P, LOHSE, DAN, MAK, CHI CHING, NORONHA, GLENN, RENICK, JOEL, CAO, JON JIANGUO, SOLL, RICHARD M, ZENG, BINQI
Format Patent
LanguageEnglish
Published 30.09.2011
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Disclosed are substituted pyrimidine compounds of formula (A) where the substituents are as disclosed in the description. Examples of compounds of formula (A) are: N-tert-Butyl-2-methyl-5- { 5-methyl-2-[ 4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino ]-pyrimidin-4-ylamino} -benzenesulfonamide; N4-(3-tert-butylphenyl)-5-methyl-N2-( 4-(1-morpholinoethyl)-phenyl)pyrimidine-2,4-diamine Hydrochloride; and 4-[4-(4-Methoxy-phenylamino)-pyrimidin-2-ylamino ]-N -(2-pyrrolidin-1-yl-ethyl)-benzenesulfonamide trifiuoroacetate. The compounds are useful for JAK family kinase interactions. Also disclosed is a pharmaceutical composition comprising a compound of formula (A); the use of a compound of formula (A) in the manufacture of a medicament to treat an angiogenic-associated disorder and the method for making a compound.
Bibliography:Application Number: NZ20060567851